Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Intracellular Th
ITCICurrent price
75.26 USD
-0.49 USD (-0.65%)
Last closed
75.38 USD
Company
www.intracellulartherapies.com
ISIN
US46116X1019
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Exchange
NASDAQ
Capitalization
7 965 178 368 USD
Yield for 12 month
+39.60 %
1Y
3Y
5Y
10Y
15Y
ITCI
Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York. Address: 430 East 29th Street, New York, NY, United States, 10016
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
95.84 USDP/E ratio
–Dividend Yield
–Current Year
+462 175 000 USD
Last Year
+249 132 000 USD
Current Quarter
+161 388 000 USD
Last Quarter
+144 866 000 USD
Current Year
+428 430 000 USD
Last Year
+228 689 000 USD
Current Quarter
+150 034 000 USD
Last Quarter
+134 966 000 USD
Key Figures ITCI
1 year
3 years
5 years
10 years
EBITDA
-111 953 000 USD
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-6.91 %
PEG Ratio
–
Return On Equity TTM
-9.63 %
Wall Street Target Price
95.84 USD
Revenue TTM
564 526 016 USD
Book Value
10.84 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
45.7 %
Dividend Yield
–
Gross Profit TTM
95 156 000 USD
Earnings per share
-0.86 USD
Diluted Eps TTM
-0.86 USD
Most Recent Quarter
II 2024
Quarterly Earnings Growth YOY
–
Profit Margin
-14.93 %
Dividend Analytics ITCI
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History ITCI
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
–
Payout Ratio
–
Last Split Date
–
Dividend Date
–
Stock Valuation ITCI
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
113.6364
Enterprise Value Revenue
12.3538
Price Sales TTM
14.1095
Enterprise Value EBITDA
-37.1202
Price Book MRQ
6.9588
Financials ITCI
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators ITCI
For 52 weeks
45.5 USD
84.89 USD
50 Day MA
75.59 USD
Shares Short Prior Month
2 542 703
200 Day MA
70.2 USD
Short Ratio
4.1
Shares Short
2 425 188
Short Percent
2.63 %
BeatStart